NASDAQ:IOSP - Free Report ) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 8,574 shares of the specialty chemicals company's stock, valued at approximately $1,057,000.
Get Innospec alerts:
Sign Up
Several other institutional investors also recently bought and sold shares of the stock. Bahl & Gaynor Inc. boosted its holdings in Innospec by 3.4% during the 4th quarter. Bahl & Gaynor Inc. now owns 36,001 shares of the specialty chemicals company's stock valued at $4,437,000 after acquiring an additional 1,177 shares during the period. GAMMA Investing LLC purchased a new stake in Innospec during the 4th quarter valued at about $44,000. ZWJ Investment Counsel Inc. boosted its holdings in Innospec by 5.3% during the 4th quarter. ZWJ Investment Counsel Inc. now owns 41,936 shares of the specialty chemicals company's stock valued at $5,168,000 after acquiring an additional 2,115 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Innospec by 14.5% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,820 shares of the specialty chemicals company's stock valued at $594,000 after purchasing an additional 611 shares during the last quarter. Finally, Louisiana State Employees Retirement System bought a new position in Innospec during the 4th quarter valued at approximately $1,528,000. 96.64% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling at Innospec In other news, SVP David B. Jones sold 2,500 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $125.79, for a total value of $314,475.00. Following the completion of the transaction, the senior vice president now owns 9,664 shares of the company's stock, valued at approximately $1,215,634.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink . In related news, CEO Patrick Williams sold 9,667 shares of the firm's stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $125.01, for a total transaction of $1,208,471.67. Following the completion of the transaction, the chief executive officer now owns 164,667 shares of the company's stock, valued at approximately $20,585,021.67. The transaction was disclosed in a filing with the SEC, which can be accessed through this link . Also, SVP David B. Jones sold 2,500 shares of the firm's stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $125.79, for a total value of $314,475.00. Following the transaction, the senior vice president now directly owns 9,664 shares of the company's stock, valued at approximately $1,215,634.56. The disclosure for this sale can be found here . Insiders sold 36,500 shares of company stock valued at $4,532,959 in the last 90 days. Insiders own 1.52% of the company's stock.
Innospec Price Performance IOSP traded up $0.01 during midday trading on Friday, reaching $121.71. 77,232 shares of the company's stock traded hands, compared to its average volume of 73,844. The firm has a fifty day moving average of $123.98 and a two-hundred day moving average of $116.74. The stock has a market capitalization of $3.04 billion, a price-to-earnings ratio of 21.85 and a beta of 1.11. Innospec Inc. has a 52 week low of $91.74 and a 52 week high of $131.18.
Innospec (NASDAQ:IOSP - Get Free Report ) last released its quarterly earnings results on Tuesday, February 13th. The specialty chemicals company reported $1.84 EPS for the quarter, beating analysts' consensus estimates of $1.59 by $0.25. The business had revenue of $494.70 million during the quarter, compared to analyst estimates of $479.47 million. Innospec had a return on equity of 13.69% and a net margin of 7.14%. Innospec's quarterly revenue was down 3.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.20 EPS. Sell-side analysts forecast that Innospec Inc. will post 6.77 EPS for the current year.
Innospec Company Profile (
Free Report )
Innospec Inc develops, manufactures, blends, markets, and supplies specialty chemicals in the United States, rest of North America, the United Kingdom, rest of Europe, and internationally. The company's Fuel Specialties segment offers a range of specialty chemical products that are used as additives in additives in diesel, jet, marine, fuel oil and other fuels.
Featured Stories
Before you consider Innospec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Innospec wasn't on the list.
While Innospec currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
